Ile105Val polymorphism in the GSTP1 gene is associated with susceptibility to acute myeloid leukemia: an updated systematic review and meta-analysis.
Raphael Enrique TiongcoNeil David CayananMiljun CatacataMichael John DominguezPublished in: Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals (2024)
Background and Objective: Several genetic variations are associated with acute myeloid leukemia (AML) susceptibility, including the GSTP1 Ile105Val polymorphism. Even with the existing meta-analysis conducted on the topic, no consensus has been reached since none of the studies available performed in-depth data analysis. Hence, we performed an updated systematic review and meta-analysis in this paper to obtain more precise estimates. Materials and Methods: We searched various databases and calculated the odds ratio (OR) and 95% confidence interval (CI) to examine whether the GSTP1 Ile105Val polymorphism is associated with AML susceptibility. Further statistical analysis was also done to obtain more accurate and reliable findings. Results: A total of 15 studies are included in the systematic review, but only 9 were included in the meta-analysis due to the studies deviating from the Hardy-Weinberg equilibrium. The analysis showed significantly increased susceptibility to AML in the allelic, co-dominant, and recessive models. Furthermore, subgroup analysis noted increased AML susceptibility in the non-Asian population. Comparing the proportions of the genotypes and alleles showed a significantly higher proportion of the Val/Val genotype and Val allele in the non-Asian cohort. Conclusion: The GSTP1 Ile105Val polymorphism is significantly associated with AML susceptibility, especially among non-Asians. Further investigation should be performed to strengthen the current results.
Keyphrases
- acute myeloid leukemia
- systematic review
- meta analyses
- allogeneic hematopoietic stem cell transplantation
- case control
- data analysis
- genome wide
- copy number
- gene expression
- clinical trial
- optical coherence tomography
- mass spectrometry
- intellectual disability
- dna methylation
- transcription factor
- machine learning
- autism spectrum disorder
- big data
- open label
- duchenne muscular dystrophy
- double blind